DrugPatentWatch Database Preview

Details for Patent: 9,504,647

« Back to Dashboard

Which drugs does patent 9,504,647 protect, and when does it expire?

Patent 9,504,647 protects NOCDURNA and is included in one NDA.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 9,504,647

Title:	Pharmaceutical formulations of desmopressin
Abstract:	Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Inventor(s):	Nilsson; Anders (Lund, SE), Lindner; Hans (Berlin, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee:	FERRING B.V. (Hoofddorp, NL)
Application Number:	14/947,261
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,504,647
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Process; Dosage form;

Drugs Protected by US Patent 9,504,647

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-001	Jun 21, 2018		RX	Yes	No			Y			TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-002	Jun 21, 2018		RX	Yes	Yes			Y			TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

International Family Members for US Patent 9,504,647

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	039092
Argentina	039794
Argentina	107948